// App-Quantinova.ai

TPS664 : RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain metastasis from HER2-positive breast cancer-A collaborative study of RTOG and KROG (NCT01622868).

Researchers

Presenter

  • David M. Peereboom

Principal Investigators

  • Kathryn A. Winter

  • Julia R. White

  • Minesh P. Mehta

  • In Ah Kim

  • Jennifer F. De Los Santos

  • Paul W. Sperduto

Medical Centers

  • Ohio State University Wexner Medical Center, Columbus, OH

  • Cleveland Clinic, Cleveland, OH

  • Metro-MN CCOP, Waconia, MN

  • University of Maryland Medical Center, Baltimore, MD

  • The University of Alabama at Birmingham Medical Center, Birmingham, AL

  • Statistical Center, Radiation Therapy Oncology Group, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Pertuzumab

  • Lapatinib

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT01622868

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved